Effects of G-CSF on the Expression of Functional Surface Markers of Neutrophils (Fc Receptors)
| A. CD . | Receptor . | Effect of G-CSF on Expression of CD64, FcR Type I . | Subjects, Clinical Background, Comments . | Reference . |
|---|---|---|---|---|
| CD64 | FcγRI | ↑ | With chemotherapy + autologous bone marrow transplantation | 132 |
| CD64 | FcγRI | ↑ | Mature neutrophils of healthy volunteers, G-CSF in vitro | 132 |
| CD64 | FcγRI | ↑ | With advanced squamous cell carcinoma, ↑ ADCC | 130 |
| CD64 | FcγRI | ↑ | With cytotoxic chemotherapy + malignancies, healthy volunteers | 131 |
| CD64 | FcγRI | ↑ | Postoperative/posttraumatic at risk of or with sepsis | 61 |
| B. CD | Receptor | Effect of G-CSF on Expression of CD32, FcR Type II | Subjects, Clinical Background, Comments | Reference |
| CD32 | FcγRII | ↑ | ↑ killing of hybridoma cell lines, application of G-CSF in vitro | 134 |
| CD32 | FcγRII | — | Healthy volunteers | 137 |
| CD32 | FcγRII | — | With cytotoxic chemotherapy + malignancies, healthy volunteers | 131 |
| CD32 | FcγRII | ↑ | With chemotherapy + autologous bone marrow transplantation | 132 |
| CD32 | FcγRII | ↑ | With non-Hodgkin lymphoma | 133 |
| CD32 | FcγRII | ↑-↓ | Postoperative/posttraumatic at risk of or with sepsis | 61 |
| C. CD | Receptor | Effect of G-CSF on Expression of CD16, FcR Type III | Subjects, Clinical Background, Comments | Reference |
| CD16 | FcγRIII | ↑ | Healthy volunteers | 75 |
| CD16 | FcγRIII | ↑ | With paroxysmal nocturnal haemoglobinuria | 135 |
| CD16 | FcγRIII | ↓ | With cytotoxic chemotherapy + malignancies, healthy volunteers | 131 |
| CD16 | FcγRIII | ↓ | With chemotherapy + autologous bone marrow transplantation | 132 |
| CD16 | FcγRIII | — | With non-Hodgkin lymphoma | 133 |
| CD16 | FcγRIII | — | Postoperative/posttraumatic at risk of or with sepsis | 61 |
| A. CD . | Receptor . | Effect of G-CSF on Expression of CD64, FcR Type I . | Subjects, Clinical Background, Comments . | Reference . |
|---|---|---|---|---|
| CD64 | FcγRI | ↑ | With chemotherapy + autologous bone marrow transplantation | 132 |
| CD64 | FcγRI | ↑ | Mature neutrophils of healthy volunteers, G-CSF in vitro | 132 |
| CD64 | FcγRI | ↑ | With advanced squamous cell carcinoma, ↑ ADCC | 130 |
| CD64 | FcγRI | ↑ | With cytotoxic chemotherapy + malignancies, healthy volunteers | 131 |
| CD64 | FcγRI | ↑ | Postoperative/posttraumatic at risk of or with sepsis | 61 |
| B. CD | Receptor | Effect of G-CSF on Expression of CD32, FcR Type II | Subjects, Clinical Background, Comments | Reference |
| CD32 | FcγRII | ↑ | ↑ killing of hybridoma cell lines, application of G-CSF in vitro | 134 |
| CD32 | FcγRII | — | Healthy volunteers | 137 |
| CD32 | FcγRII | — | With cytotoxic chemotherapy + malignancies, healthy volunteers | 131 |
| CD32 | FcγRII | ↑ | With chemotherapy + autologous bone marrow transplantation | 132 |
| CD32 | FcγRII | ↑ | With non-Hodgkin lymphoma | 133 |
| CD32 | FcγRII | ↑-↓ | Postoperative/posttraumatic at risk of or with sepsis | 61 |
| C. CD | Receptor | Effect of G-CSF on Expression of CD16, FcR Type III | Subjects, Clinical Background, Comments | Reference |
| CD16 | FcγRIII | ↑ | Healthy volunteers | 75 |
| CD16 | FcγRIII | ↑ | With paroxysmal nocturnal haemoglobinuria | 135 |
| CD16 | FcγRIII | ↓ | With cytotoxic chemotherapy + malignancies, healthy volunteers | 131 |
| CD16 | FcγRIII | ↓ | With chemotherapy + autologous bone marrow transplantation | 132 |
| CD16 | FcγRIII | — | With non-Hodgkin lymphoma | 133 |
| CD16 | FcγRIII | — | Postoperative/posttraumatic at risk of or with sepsis | 61 |
Abbreviations: ↑, increase; —, no effect; ↓, decrease.